“…We then further verified the systemic immunostimulatory effect of the MLSV system in vivo . To this end, mice were injected with DMP, tumor cell lysate, or the MLSV system, and related expression in LNs and spleens was monitored for 72 h. − As shown in Figure D, the percentage of CD11c + cells in LNs in the MLSV group was 66.9 ± 2.9% (peak value at 72 h), which was higher than those of the tumor cell lysate group (56.5 ± 2.7%, P < 0.001, peak value at 72 h), the DMP group (43.8 ± 3.6%, P < 0.001, peak value at 72 h), and the NS group (8.4 ± 1.4%, P < 0.001, peak value at 72 h). The percentage of CD11c + CD80 + cells in the MLSV group was 76.4 ± 1.5% (peak value at 72 h), which exceeded those of the tumor cell lysate group (47.4 ± 2.1%, P < 0.001, peak value at 72 h), the DMP group (25.2 ± 1.1%, P < 0.001, peak value at 72 h), and the NS group (16.9 ± 1.8%, P < 0.001, peak value at 72 h) (Figure D).…”